Leishmaniasis

Disease complex - species of Leishmania

Distribution of VL

Control and Elimination of Visceral Leishmaniasis

Simon Croft
London School of Hygiene and Tropical Medicine
Simon.Croft@lshtm.ac.uk
Tackling Visceral Leishmaniasis in South Asia and East Africa

- UK aid funded programme
- 4 year timeframe 2014-2018
- Countries:
  South Asia-India, Bangladesh, Nepal
  East Africa-Ethiopia, Sudan, South Sudan
Programme Aim:
To reduce the health and economic impact of visceral leishmaniasis through supporting efforts towards elimination in South Asia and better control of the disease in East Africa

Through KalaCORE, leading scientific experts and practitioners work with host Governments and local implementing partners, including World Health Organization, NGOs and universities, to implement programmes for improved diagnosis, treatment, prevention and surveillance of VL.

The KalaCORE programme has focused interventions that ensure mass coverage of people protected through the wide reach of its activities and treatment centres.

KalaCORE brings together:

15-Feb-17
**PEOPLE PROTECTED BY ACCESS TO VL DIAGNOSIS AND TREATMENT**

Population coverage:

- **70,409,011**
- **29,057,965**
  - India
  - Ethiopia
  - Sudan
  - South Sudan
- **24,580,353**
- **4,079,955**

Total: **128,127,284**

**VL patients diagnosed and treated in 2016: 11,005**

**People reached with BCC/IEC Total: 2,552,130**

OUTBREAK RESPONSE: KalaCORE's mobile teams investigated 7 suspected outbreaks in South Sudan in 2016
Poverty Focus

Baselines confirm the poor suffer the highest burden as a result of VL. In over 12% of affected households, costs of seeking treatment accounted for over 40% of total annual household expenditure. KalaCORE is reducing this burden through reducing the time between onset of symptoms, effective diagnosis and proper treatment.

Gender Focus

VL affects more men than women worldwide, and available data suggests women are equally likely to access treatment. 44% of VL cases treated in India and South Sudan KalaCORE supported facilities were female.

Health Systems Strengthening Focus

Clinical mentoring improves quality of care and decreases burdens on health systems. Mentoring to introduce SSG+PM combination therapy in Africa has reduced treatment time from 30 to 17 days. KalaCORE has also introduced single dose Ambisome in Asia, and strengthened the cold chain.

Active Case Detection

587,661 people screened in 219 villages in India. From which 37 VL and 172 PKDL cases were confirmed. Low incidence indicates elimination targets are well within sight in India.
Thanks for your attention